ERBB2 and breast carcinoma: Anti-HER2 treatment was added in patients with HER2-positive breast cancers, which constituted around 35.3% of patient population, in the form of trastuzumab alone [19, 21–23, 26, 29, 32] or trastuzumab/pertuzumab combination [20, 21, 32].